Previous 10 | Next 10 |
Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announces the publication of its Sustainability Report 2021. The report showcases the Group ...
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries announced today that all resolutions proposed to Shareholders at the Annual General Meeting of Sha...
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences. On June 7, 2...
Stevanato Group (NYSE:STVN) said Tuesday it acquired a new industrial complex in Cisterna di Latina, Italy, strengthening its presence in Europe. The brownfield facility will be partly powered by renewable sources, adding production capabilities and technologies to complement STVN's existing ...
Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced the acquisition of a new industrial complex in Cisterna di Latina, Italy. The ne...
Stevanato Group S.p.A. (STVN) Q1 2022 Results Conference Call May 10, 2022 08:30 AM ET Company Participants Lisa Miles - Head of Investor Relations Franco Stevanato - Executive Chairman Franco Moro - Chief Executive Officer and Chief Operating Officer Marco Dal Lago - Chief Financial Officer ...
Image source: The Motley Fool. Stevanato Group S.p.A. (NYSE: STVN) Q1 2022 Earnings Call May 10, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Stevanato Group S.p.A. (STVN) Q1 2022 Earnings Call Transcript
Stevanato Group press release (NYSE:STVN): Q1 Non-GAAP EPS of €0.11. Revenue of €212.1M (+10.0% Y/Y). Adjusted EBITDA totaled €54.0 million with an adjusted EBITDA margin of 25.5%. Backlog increased 49% to approximately €992.2 million. The Company is maintaining it...
- The Company is Maintaining its Fiscal 2022 Guidance - Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financi...
Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it has published the agenda for the 2022 Annual General Meeting of Shareholders (“AGM”), w...
News, Short Squeeze, Breakout and More Instantly...
Stevanato Group S.p.A. Company Name:
STVN Stock Symbol:
NYSE Market:
Stevanato Group S.p.A. Website:
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the second quarter of 2024 on Tuesday, August 6, 2...
2024-07-04 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-24 21:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...